Some sort of common cancer-causing proteins known as MYC stimulates the growth of tumour cells simply by ensuring that RNA transcripts tend to be adequately spliced, according to latest work from A*STAR researchers. Medicines which cell's splicing machinery may provide a brand-new way to halt the proliferation of MYC-driven cancers.
The MYC oncoprotein is a central driver in the majority of human cancers. MYC binds to active regulatory elements in the genome and broadly amplifies gene expression, leading to rampant cell growth. This process, however, is not random or indiscriminate. Guccione, in collaboration with colleagues in Italy, recently showed that MYC preferentially activates distinct subsets of target genes to control cellular states. Further research by Guccione and colleagues revelaed that a link between MYC overexpression and the activity of spliceosome-related genes.
Notably, high expression of PRMT5 correlated with worse clinical outcomes. In the laboratory, knocking out PRMT5, or another core component of the splicing machinery in human lymphoma cells lines, also reduced cell viability.
Source: The Agency for Science, Technology and Research (A*STAR)
Submit research at: Cancer biology and Therapeutics